LOGIN  |  REGISTER
Amneal Pharmaceuticals
Amneal Pharmaceuticals

CONMED to Present at the BofA Securities Healthcare Conference

May 01, 2024 | Last Trade: US$75.50 0.96 1.29

LARGO, Fla. / May 01, 2024 / Business Wire / CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m. ET) on Tuesday, May 14, 2024 in Las Vegas, NV.

A live audio webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.conmed.com and will be available for replay following the event.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated webcast may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2023 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Surmodics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB